GPCR Structure Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1888886 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-39.5%
TTM EPS YoY-6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.5%
ROA-27.1%
ROIC (approx.)-32.3%
Asset turnover—
Leverage & solvency
Liabilities / assets8.4%
Debt / equity0.00x
Current ratio11.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $134.55M | $100.06M | $66.51M | $68.69M | $58.99M | $54.71M | $42.87M | $33.49M |
| SG&A expense | $21.78M | $18.57M | $22.87M | $17.57M | $14.80M | $15.74M | $13.44M | $13.57M |
| Operating income | -$156.33M | -$118.63M | -$89.38M | $23.99M | -$73.79M | -$70.45M | -$56.31M | -$47.06M |
| Pretax income | -$144.59M | -$105.92M | -$75.78M | $33.17M | -$65.60M | -$61.52M | -$46.73M | -$36.34M |
| Income tax | $171,000 | $234,000 | $190,000 | $170,000 | $108,000 | $139,000 | $98,000 | $136,000 |
| Net income | -$144.76M | -$106.16M | -$75.97M | $33.00M | -$65.71M | -$61.66M | -$46.83M | -$36.48M |
| EBITDA | -$156.27M | -$118.08M | -$88.80M | $24.40M | -$73.43M | -$70.16M | -$56.04M | -$46.79M |
| EPS (basic) | -0.66 | -0.49 | -0.35 | — | -0.37 | -0.36 | -0.27 | — |
| EPS (diluted) | -0.66 | -0.49 | -0.35 | — | -0.37 | -0.36 | -0.27 | — |
| Weighted avg. shares (diluted) | 218.58M | 217.96M | 217.33M | — | 175.47M | 172.65M | 172.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $222.03M | $272.64M | $316.17M | $799.62M | $102.91M | $147.02M | $152.12M | $169.51M |
| Short-term investments | $1.02B | $1.07B | $1.14B | $646.57M | $696.13M | $639.47M | $684.76M | $714.01M |
| Current assets | $1.28B | $1.37B | $1.49B | $1.57B | $814.02M | $799.30M | $849.62M | $891.21M |
| PP&E, net | $10.26M | $6.33M | $6.37M | $6.65M | $4.67M | $3.46M | $3.52M | $3.48M |
| Total assets | $1.33B | $1.43B | $1.51B | $1.58B | $832.16M | $816.44M | $866.55M | $903.33M |
| Current liabilities | $107.10M | $66.11M | $56.98M | $63.28M | $57.53M | $39.03M | $36.49M | $36.02M |
| Total liabilities | $112.55M | $71.01M | $61.03M | $67.54M | $62.14M | $44.36M | $41.91M | $38.49M |
| Shareholders' equity | $1.22B | $1.35B | $1.45B | $1.52B | $770.02M | $772.08M | $824.64M | $864.84M |
| Shares outstanding | 214.09M | 213.66M | 213.21M | 212.51M | 182.03M | 172.70M | 172.61M | 171.86M |
| Cash flow statement | ||||||||
| Operating cash flow | -$101.70M | -$120.11M | $15.23M | -$64.42M | -$51.00M | -$54.56M | -$52.23M | -$36.47M |
| Capital expenditure | $3.65M | -$42,000 | $1.18M | $1.50M | $1.57M | $232,000 | $314,000 | $16,000 |
| Free cash flow | -$105.34M | -$120.07M | $14.05M | -$65.91M | -$52.57M | -$54.79M | -$52.54M | -$36.48M |
| Investing cash flow | $50.36M | $74.50M | -$496.95M | $56.14M | -$49.32M | $48.94M | $34.03M | $33.23M |
| Financing cash flow | $734,000 | $2.08M | -$1.74M | $704.99M | $56.20M | $517,000 | $809,000 | $615,000 |
| Depreciation & amortization | $61,000 | $551,000 | $576,000 | $412,000 | $356,000 | $291,000 | $274,000 | $273,000 |
| Stock-based compensation | $12.73M | $12.63M | $11.64M | $8.07M | $7.50M | $7.51M | $5.92M | $5.83M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.